Overview

Losartan in Treating Patients With Idiopathic Pulmonary Fibrosis

Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Losartan may be effective in treating patients with idiopathic pulmonary fibrosis. PURPOSE: This clinical trial is studying the side effects of losartan and to see how well it works in treating patients with idiopathic pulmonary fibrosis.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of South Florida
Collaborator:
National Cancer Institute (NCI)
Treatments:
Losartan
Criteria
INCLUSION CRITERIA:

- Age > 21 years

- Diagnosis of idiopathic pulmonary fibrosis

- Patients taking Coumadin and/or N-acetylcysteine may participate in the study

- Baseline forced vital capacity (FVC) must be greater than or equal to 50%

- Baseline 6 minute walk test distance walked must be greater than or equal to 200
meters not requiring greater than 6 lpm of oxygen

EXCLUSION CRITERIA:

- Pregnant, intending to become pregnant or breastfeeding

- Current or previous smoker of cigarettes or marijuana that recently quit within the
last 6 months prior to enrollment

- Allergy or allergic reaction to Losartan or any other angiotensin II receptor blocker

- Taking losartan or any other angiotensin II receptor blocker

- Baseline systolic blood pressure < 100 mmHg

- Currently taking or has taken immunosuppressant agents within the last month such as
azathioprine, cyclophosphamide, colchicine and/or prednisone

- History of lung transplant

- History of kidney failure or liver disease

- Inability to attend clinic visits